用Mn3O4纳米颗粒对皮里米丁药物进行药理动力学和分子对接研究,以探索潜在的抗阿尔茨海默症活性
Wesam S Shehab1, Hend A Haikal2, Doaa A Elsayed2
1Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt. dr.wesamshehab@gmail.com.
Scientific reports
|July 4, 2024
概括
研究人员使用四氧化纳米粒子 (Mn3O4-NPs) 开发了新的阿尔茨海默病 (AD) 候选药物. 合成的化合物通过向TNF-α转化酶显示了治疗AD的潜力.
科学领域:
- 药用化学 医学化学
- 纳米技术纳米技术
- 神经科学是一个神经科学.
背景情况:
- 阿尔茨海默氏病 (AD) 是导致痴呆的主要原因,与胆固醇缺乏症有关.
- 瘤坏死因子-α (TNF-α) 与炎症性疾病有关,是治疗点.
- 现有的AD治疗方法包括胆酶抑制剂,但需要新的方法.
研究的目的:
- 合成新型化合物作为阿尔茨海默病的潜在治疗剂.
- 利用四氧化纳米粒子 (Mn3O4-NPs) 作为化合物合成的有效催化剂.
- 通过与TNF-α转化酶对接来评估合成化合物的潜力.
主要方法:
- 由Mn3O4-NPs催化的一种多成分比尼内利反应被用来合成一种胺衍生物 (化合物1).
- 化合物1通过与各种化和化剂的反应进一步进行了修饰.
- 在基分子对接研究中进行了评估合成化合物与TNF-α转化酶的结合亲和力.
主要成果:
- 在环境友好的条件下,成功合成了一系列基于胺的新型化合物.
- 使用Mn3O4-NP的合成被证明是高效,安全和节省时间的.
- 几种合成的化合物表现出有利的药理动力学特性和对TNF-α转化酶有希望的对接分数.
结论:
- 开发的合成策略为新型化合物提供了一条绿色和高效的途径,在阿尔茨海默病中具有潜在的治疗应用.
- 合成的化合物代表了作为抗阿尔茨海默氏症药物的进一步开发的有希望的候选人.
- 用这些新型化合物准TNF-α转化酶可能为阿尔茨海默病治疗提供新的治疗途径.
更多相关视频
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
458
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
11.9K
相关概念视频
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
